Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

0A4Y

Aim Immunotech (0A4Y)

Aim Immunotech Inc
De:
Trier par:
 Showing the most relevant articles for your search:LSE:0A4Y
DateHeureSourceTitreSymboleSociété
09/05/202414h50UK RegulatoryAIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastLSE:0A4YAim Immunotech Inc
06/05/202414h30UK RegulatoryAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®LSE:0A4YAim Immunotech Inc
29/04/202414h55UK RegulatoryAIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerLSE:0A4YAim Immunotech Inc
10/04/202414h21UK RegulatoryAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerLSE:0A4YAim Immunotech Inc
02/04/202413h30UK RegulatoryAIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateLSE:0A4YAim Immunotech Inc
26/03/202414h05UK RegulatoryAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastLSE:0A4YAim Immunotech Inc
25/03/202414h05UK RegulatoryAIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchLSE:0A4YAim Immunotech Inc
07/03/202414h45UK RegulatoryAIM ImmunoTech Announces Launch of CEO Corner PlatformLSE:0A4YAim Immunotech Inc
29/02/202414h45UK RegulatoryAIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateLSE:0A4YAim Immunotech Inc
14/02/202414h55UK RegulatoryAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic CancerLSE:0A4YAim Immunotech Inc
 Showing the most relevant articles for your search:LSE:0A4Y